Preeclampsia (PE) is characterized by hypertension and proteinuria after the 20th gestational week (GW). It is a significant cause of maternal and fetal perinatal morbidity and mortality during pregnancy. There is increasing evidence suggesting that PE is due to an impaired balance between maternal placental angiogenic and antiangiogenic factors that harm maternal vascular endothelium. The study aimed to assess the clinical and financial aspects of introducing into practice the soluble fms-like tyrosine kinase (sFlt-1) to placental growth factor (PlGF) ratio test to improve the management of preeclampsia and adverse pregnancy outcome, intrauterine growth retardation, iatrogenic prematurity, and placental abruption.
We report a case study in which we used the sFlt-1/PlGF ratio in the management of a high-risk pregnancy. Unnecessary hospitalization was avoided, and the patient was managed appropriately.
-term neurodevelopmental outcomes after intrauterine and neonatal insults: a systematic review. Lancet. 2012; 379: 445. 11. Goldenberg R. L, Hauth J. C, Andrews W. W. Intrauterine infection and preterm delivery. N. Engl. J. Med. 2000; 342(20): 1500-1507. 12. Kramer M. S. The epidemiology of adversepregnancyoutcomes: an overview. J Nutr. 2003; 133: 1592S-1596S. 13. Pretorius C, Jagatt A, Lamont R. F. The relationship between periodontal disease, bacterial vaginosis, and preterm birth. J Perinat Med. 2007; 35(2): 93-9. 14. Klebanoff M, Searle K. The role of inflammation in preterm birth
. Intrauterine infection and preterm delivery. N. Engl. J. Med. 2000;342(20), 1500–1507 8. Kramer MS. The epidemiology of adversepregnancyoutcomes: an overview. J Nutr.2003; 133:1592S1596S. 9. Pretorius C, Jagatt A, Lamont RF. The relationship between periodontal disease, bacterial vaginosis, and preterm birth. J Perinat Med. 2007;35(2):93-9 10. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn JE. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for
BMI on lifetime risk for diabetes in the U. S. Diabetes Care 30: 1562-1566, 2007. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes Care 25: 829-834, 2002. HAPO Study Cooperative Research Group. Hyperglycemia and AdversePregnancyOutcome (HAPO) Study: Intl J Gynecol Obstet 78: 69-77, 2002. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Coustan DR
Northern Ireland: population based study. BMJ 333: 177, 2006. 7. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP et al. Hyperglycemia and adversepregnancyoutcomes. N Engl J Med 358: 1991-2002, 2008. 8. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy.. Diabetes Care 33: 676-682, 2010. 9. Roman G, Crăciun A. Diabetul zaharat şi sarcina. In
. Poor glycated haemoglobin control and adversepregnancyoutcomes in type 1 and type 2 diabetes mellitus: systematic review of observational studies. BMC Pregnancy Childbirth 6:30, 2006. 14. Nielsen GL, Moller M, Sorensen HT. HbA1c in early diabetic pregnancy and pregnancy outcomes. A Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care 29:2612-2616, 2006. 15. Jensen DM, Korsholm L, Pet O et al. Periconceptional A1C and risk of serious adversepregnancyoutcome in 933 women with type 1 diabetes. Diabetes Care 32
diabetes. Diabetes Care 2003;26:1199-1205. 10. “Bird” Hoffert Gilmartin, Serdar H. Ural, MD, John T. Repke, Gestational Diabetes Mellitus Rev Obstet Gynecol. 2008;1(3):129-134. 11. Canadian Diabetes Association 2008. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Gestational diabetes mellitus. Diabetes and Pregnancy. Can J Diabetes. 2008; 32(Suppl 1):S168-S180. 12. Hapo Study Cooperative Research Group. Hyperglycaemia and adversepregnancyoutcomes. N Eng J Med. 2008;358:1991-2002. 13. Jović N., Varjačić M., Nenadović Živanović A
prophylactic cervical cerclage simplified from the Shirodkar cerclage: Journal of Gynecology Obstetrics and Human Reproduction, 2017, 46 (4): 343-347, doi: 10.1016/j.jogoh.2017.02.003 8. Vincenzo Berghella. Cervical cerclage for the woman with prior adversepregnancyoutcome: Contemporary OB/GYN, Volume 55, 2010, Number 6, 18-20 9. Suhag A., Seligman N.S., Bianchi I. What is the optimal gestational age for history-indicated cerclage placement?: American Journal of Perinatology, 2010, 27(6): 469-474 10. Anthony O.Odibo, Vincenzo Berghella, Meekai S. Shirodkar versus McDonald
women without gestational diabetes. The Toronto Tri-Hospital Gestational Diabetes Project. Am J Obstet Gynecology 173: 146-156, 1995. 10. Sermer M, Naylor CD, Farine D et al. The Toronto Tri-Hospital Gestational Diabetes Project: A preliminary review. Diabetes Care 21[Supp 2]: B33- B42, 1998. 11. HAPO Study Cooperative Research Group Metzger BE, Lowe LP et al. Hyperglycemia and adversepregnancyoutcomes. N Engl J Med 358: 1991- 2002, 2008. 12. O’Sullivan JB. Gestational Diabetes and its Significance. In: Early Diabetes. Camerini-Davalos, Cole HS (eds